



CA19-9 (SPM110): sc-56506

BACKGROUND

Blood-group antigens are generally defined as molecules formed by sequential addition of saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and certain epithelial cells. The A, B and H antigens are reported to undergo modulation during malignant cellular transformation. Blood group related antigens are usually mucin-type, and are detected on erythrocytes, certain epithelial cells and in secretions of certain individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong to this group of antigens, including A, B, H, Lewis a, Lewis b, Lewis x, Lewis y, CA19-9 and precursor type 1 chain antigens. CA19-9 is associated with colon, pancreatic and endometrial cancer, as well as intestinal metaplasia.

REFERENCES

1. King, M.J. and Holburn, A.M. 1979. Radioassays of blood group M, N and T (Thomsen-Friedenreich) antigens. *Immunology* 38: 129-136.
2. Watkins, W.M. 1980. Biochemistry and genetics of the ABO, Lewis and P blood group systems. *Adv. Hum. Genet.* 10: 1-136, 379-385.
3. Gupta, M.K., Arciaga, R., Bocci, L., Tubbs, R., Bukowski, R. and Deodhar, S.D. 1985. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. *Cancer* 56: 277-283.
4. Otsuka, K., Kudo, T., Nakajima, T. and Ohkuma, S. 1991. Blood group N antigen precursor glycoproteins and N antigen precursor glycoproteins with Thomsen-Friedenreich (T) activity from human liver metastatic carcinomas. *Int. J. Biochem.* 23: 569-578.
5. Murata, K., Egami, H., Shibata, Y., Sakamoto, K., Misumi, A. and Ogawa, M. 1992. Expression of blood group-related antigens, A, B, H, Lewis a, Lewis b, Lewis x, Lewis y, CA19-9 and CSLEX1 in early cancer, intestinal metaplasia and uninvolved mucosa of the stomach. *Am. J. Clin. Pathol.* 98: 67-75.
6. Boren, T., Falk, P., Roth, K.A., Larson, G. and Normark, S. 1993. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. *Science* 262: 1892-1895.
7. Takeshima, N., Shimizu, Y., Umezawa, S., Hirai, Y., Chen, J.T., Fujimoto, I., Yamauchi, K. and Hasumi, K. 1994. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. *Gynecol. Oncol.* 54: 321-326.
8. Fisher, A., Theise, N.D., Min, A., Mor, E., Emre, S., Pearl, A., Schwartz, M.E., Miller, C.M. and Sheiner, P.A. 1995. CA19-9 does not predict cholangio-carcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. *Liver Transpl. Surg.* 1: 94-98.
9. Heinemann, V., Schermuly, M.M., Stieber, P., Schulz, L., Jüngst, D., Wilkowski, R. and Schalhorn, A. 1999. CA19-9: a predictor of response in pancreatic cancer treated with gemcitabine and cisplatin. *Anticancer Res.* 19: 2433-2435.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

CA19-9 (SPM110) is a mouse monoclonal antibody raised against purified CA19-9 of human origin.

PRODUCT

Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

CA19-9 (SPM110) is recommended for detection of the CA19-9 epitope (Sialyl Lewis a containing glycolipids) of human origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 2) Immunohistochemistry: use ImmunoCruz™: sc-2050 or ABC: sc-2017 mouse IgG Staining Systems.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.